[go: up one dir, main page]

MXPA02004574A - Formulacion farmaceutica que contiene tolterodina y su uso. - Google Patents

Formulacion farmaceutica que contiene tolterodina y su uso.

Info

Publication number
MXPA02004574A
MXPA02004574A MXPA02004574A MXPA02004574A MXPA02004574A MX PA02004574 A MXPA02004574 A MX PA02004574A MX PA02004574 A MXPA02004574 A MX PA02004574A MX PA02004574 A MXPA02004574 A MX PA02004574A MX PA02004574 A MXPA02004574 A MX PA02004574A
Authority
MX
Mexico
Prior art keywords
controlled release
layer
producing
release bead
same
Prior art date
Application number
MXPA02004574A
Other languages
English (en)
Inventor
Torkel Gren
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56290073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02004574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Priority claimed from SE0000782A external-priority patent/SE0000782D0/xx
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MXPA02004574A publication Critical patent/MXPA02004574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a una formulacion farmaceutica que contiene tolterodina o un compuesto relacionado a la tolterodina, o una sal farmaceuticamente aceptable de la misma, como ingrediente activo, en el cual la formulacion exhibe una liberacion in vitro controlada del ingrediente activo en amortiguador de fosfato a un pH 6.8 de no menor que aproximadamente el 80% despues de 18 horas, y despues de la administracion oral a un paciente este es capaz de mantener un nivel de suero substancialmente constante de la porcion o porciones activas por 24 horas. La invencion tambien se refiere al uso de la formulacion farmaceutica para tratar una vejiga urinaria hiperactiva y desordenes gastrointestinales.
MXPA02004574A 1999-11-11 2000-10-24 Formulacion farmaceutica que contiene tolterodina y su uso. MXPA02004574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use

Publications (1)

Publication Number Publication Date
MXPA02004574A true MXPA02004574A (es) 2004-09-10

Family

ID=56290073

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004574A MXPA02004574A (es) 1999-11-11 2000-10-24 Formulacion farmaceutica que contiene tolterodina y su uso.

Country Status (24)

Country Link
US (1) US6630162B1 (es)
EP (1) EP1227806B1 (es)
JP (1) JP2003513918A (es)
KR (2) KR100838930B1 (es)
CN (1) CN100353935C (es)
AT (1) ATE300941T1 (es)
AU (1) AU784104B2 (es)
BR (1) BR0015346A (es)
CA (1) CA2387973C (es)
CZ (1) CZ304671B6 (es)
DE (1) DE60021749T2 (es)
DK (1) DK1227806T3 (es)
EE (1) EE05191B1 (es)
ES (1) ES2245320T3 (es)
HK (1) HK1054196B (es)
HU (1) HUP0203028A3 (es)
MX (1) MXPA02004574A (es)
NO (1) NO20022264L (es)
NZ (1) NZ518309A (es)
PL (1) PL356166A1 (es)
PT (1) PT1227806E (es)
SI (1) SI1227806T1 (es)
SK (1) SK6412002A3 (es)
WO (1) WO2001034139A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
KR100838930B1 (ko) * 1999-11-11 2008-06-16 화이자 헬스 에이비 톨테로딘을 포함하는 약학 제제 및 이의 용도
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
WO2004064821A1 (en) † 2003-01-22 2004-08-05 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
SE0300830D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
CN1795845B (zh) * 2004-12-23 2010-10-13 李又欣 作为毒蕈碱受体拮抗剂的3，3-二苯基丙胺衍生物注射用缓释微球制剂
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
CZ2006506A3 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
EP2231124A1 (en) * 2007-12-20 2010-09-29 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
EP2398469A4 (en) * 2009-02-23 2013-09-04 Aptalis Pharmatech Inc ANTICHOLINERGIC CONTAINING DELAYED RELEASE COMPOSITION
CA2769760A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US20130004545A1 (en) 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8392016B2 (en) 2010-06-25 2013-03-05 LNT PM Inc. Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
MX2017003561A (es) * 2014-08-22 2017-08-28 Medipath Inc Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
DK3405191T3 (da) 2016-01-20 2025-05-19 Theravida Inc Sammensætninger til anvendelse ved behandling af hyperhidrose
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ATE185694T1 (de) 1992-05-13 1999-11-15 Alza Corp Oxybutynin zur transdermalen verabreichung
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
JP2001502302A (ja) 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
JPH11193271A (ja) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SI1039882T1 (sl) * 1998-08-27 2011-01-31 Pfizer Health Ab Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
KR100838930B1 (ko) * 1999-11-11 2008-06-16 화이자 헬스 에이비 톨테로딘을 포함하는 약학 제제 및 이의 용도

Also Published As

Publication number Publication date
HUP0203028A2 (hu) 2003-02-28
BR0015346A (pt) 2002-06-25
US6630162B1 (en) 2003-10-07
KR100838930B1 (ko) 2008-06-16
JP2003513918A (ja) 2003-04-15
PT1227806E (pt) 2005-10-31
CA2387973A1 (en) 2001-05-17
DE60021749D1 (de) 2005-09-08
ATE300941T1 (de) 2005-08-15
CN100353935C (zh) 2007-12-12
HUP0203028A3 (en) 2005-07-28
CZ20021617A3 (cs) 2002-11-13
EP1227806B1 (en) 2005-08-03
EP1227806A1 (en) 2002-08-07
SK6412002A3 (en) 2002-09-10
NZ518309A (en) 2003-05-30
HK1054196A1 (zh) 2003-11-21
DK1227806T3 (da) 2005-10-31
AU784104B2 (en) 2006-02-02
CA2387973C (en) 2009-12-22
KR20070091374A (ko) 2007-09-10
SI1227806T1 (sl) 2005-12-31
DE60021749T2 (de) 2006-04-20
NO20022264D0 (no) 2002-05-13
WO2001034139A1 (en) 2001-05-17
PL356166A1 (en) 2004-06-14
HK1054196B (zh) 2008-08-01
CZ304671B6 (cs) 2014-08-27
CN1420767A (zh) 2003-05-28
NO20022264L (no) 2002-05-13
EE05191B1 (et) 2009-08-17
EE200200245A (et) 2003-06-16
AU1319201A (en) 2001-06-06
ES2245320T3 (es) 2006-01-01
KR20020062302A (ko) 2002-07-25

Similar Documents

Publication Publication Date Title
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
YU33101A (sh) Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
CA2193129A1 (en) Transdermal drug delivery system
AU2684497A (en) Biodegradable sustained-release preparation, biodegradable pheromone dispenser and biodegradable pest controlling agent
AU3779399A (en) Drug-containing transdermal patches, plastisols and adhesives
AU7599100A (en) Control method and system for use when growing thin-films on semiconductor-basedmaterials
AU6497600A (en) Peracid forming system, peracid forming composition, and methods for making and using
EP2070517A3 (en) Pharmaceutical composition and method for treating hypogonadism
AU2963400A (en) Improved controlled release compositions and method
AU2499100A (en) Method and apparatus for selectively controlling the quantum state probability distribution of entangled quantum objects
HUP9600116A3 (en) Fungicidal composition containing benzophenone, process for preparation of the active ingredients and method for the control of fungi.
CA2338070A1 (en) Diltiazem controlled release formulation and method of manufacture
AU8109398A (en) Implants for controlled release of pharmaceutically active principles and method for making same
CA2085871A1 (en) A controlled release drug dispersion delivery device
AU4464897A (en) Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix
AU698240B2 (en) Composition providing selective release of an active ingredient
WO2001083398A3 (de) System für die freisetzung von wirkstoffen
AU7569796A (en) Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds.
CA2007353A1 (en) Superficial Therapeutic System Comprising an Antineoplastic Active Substance, Particularly 5-Fluorouracil
AU3708100A (en) Method for protecting and/or controlled release of active ingredients
AU6328700A (en) Method for immobilising physiologically active compounds
AU5320998A (en) Microparticles containing active substances, agents containing the same, their use in ultrasound-controlled releasing of active substances as well as the method for their production
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
AU1534895A (en) Weed-suppressing agent, method for preparing it and its use in weed control
AU2001286000A1 (en) Composition, method for making same, implementing device and use of liquid mycelium

Legal Events

Date Code Title Description
FG Grant or registration